|
시장보고서
상품코드
2147155
불임 치료제 시장 규모, 점유율, 성장률 - 업계 분석, 지역별 동향 및 예측(2026-2034년)Fertility Drugs Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
불임 치료제 시장의 성장 요인
세계 불임 치료제 시장 규모는 2025년에 30억 5,000만 달러로 평가되었고, 2026년 32억 4,000만 달러에서 2034년까지 52억 5,000만 달러로 성장하여, 2026-2034년의 예측 기간 동항 연평균 성장률(CAGR) 6.22%를 나타낼 것으로 전망됩니다. 2025년에는 북미가 34.1%의 점유율을 차지하며 시장을 주도하고 있으며, 해당 지역 시장 규모는 약 10억 4,000만 달러였습니다.
불임 치료제란 생식 호르몬 조절, 배란 촉진, 난포 및 난자의 발육 지원, 그리고 체외수정(IVF)이나 인공수정(IUI) 등 보조생식기술(ART)의 치료 성과 향상을 목적으로 사용되는 의약품을 말합니다. 이러한 약물은 배란 장애, 원인 불명의 불임, 다낭성 난소 증후군, 난소 예비능 저하, 그리고 조절된 난소 자극 등에 널리 사용되고 있습니다. 불임 유병률 증가, 출산 연령의 고령화, 인식 제고, 그리고 불임 치료 클리닉에 대한 접근성 확대가 시장 성장을 뒷받침하고 있습니다.
불임 치료제 시장 동향
불임의 조기 진단과 치료에 대한 인식 제고가 그 중요성을 더하고 있습니다.
불임이 일반적인 생식 건강 문제라는 인식이 확산됨에 따라, 더 많은 환자들이 진단과 치료를 찾고 있습니다. 배란 유도 요법, 고나도트로핀, 호르몬 요법, 황체기 유지제의 사용이 증가하고 있으며, 이것이 제품 수요를 뒷받침하고 있습니다.
불임 치료에 관한 보험 급여 및 비용 부담 경감 프로그램의 확충도 중요한 동향 중 하나입니다. 정부의 이니셔티브, 고용주가 지원하는 의료 혜택, 의약품 접근 프로그램 등이 약제비 절감과 치료 접근성 향상에 기여하고 있습니다.
시장 성장 촉진요인
출산 시기 지연과 고령 출산 증가가 수요를 견인하고 있습니다.
교육, 경력, 경제적 사정, 그리고 가족관에 대한 인식 변화로 인해 부모가 되는 시기를 미루는 사람들이 늘어나고 있어, 출산 연령의 상승은 주요 시장 성장 촉진요인으로 작용하고 있습니다. 나이가 들수록 자연 임신 능력이 저하되기 때문에 배란 유도, 조절된 난소 자극, 체외수정(IVF), 그리고 인공수정(IUI)과 같은 치료에 대한 수요가 증가하고 있습니다.
보조생식기술(ART) 시술 건수 증가, 불임 치료 클리닉 네트워크의 확대, 그리고 의약품 파이프라인 개발의 지속 또한 시장 성장에 기여하고 있습니다.
시장 성장 억제요인
호르몬 자극에 따른 안전성 우려가 보급을 제한하고 있습니다.
불임 치료제, 특히 난소 자극에 사용되는 고나도트로핀은 난소 과자극 증후군 등의 부작용을 유발할 가능성이 있습니다. 이러한 위험이 있으므로 환자에 대한 신중한 모니터링과 전문의 감독이 필요합니다.
높은 본인 부담금, 불균일한 보험 환급, 그리고 전문적인 생식 건강 관리에 대한 접근 제한이, 특히 개발도상국 시장에서 도입을 더욱 제한할 가능성이 있습니다.
시장 기회
고용주나 보험사의 불임 치료 급여 지원이 기회를 창출
고용주나 보험사가 불임 치료에 대한 보험 적용 범위를 확대하는 것은 큰 성장 잠재력을 내포하고 있습니다. 약제비 본인 부담금이 경감되면, 환자들이 불임 치료를 시작하고 지속할 동기가 됩니다.
또한, 보험 급여 확대는 체외수정(IVF)과 관련된 불임 치료제 사용을 촉진하여, 제약사, 약국, 불임 치료 제공업체에게 비즈니스 기회를 창출할 가능성이 있습니다.
시장의 과제
치료의 성공 여부가 불확실하다는 점은 여전히 큰 과제로 남아 있습니다. 불임 치료는 임신이나 출산을 보장하는 것이 아니며, 환자에 따라서는 여러 차례의 치료 주기가 필요할 수도 있습니다. 치료의 반복은 약제비 증가, 정신적 스트레스, 치료에 대한 피로감을 초래하며, 그 결과 환자가 치료를 연기하거나 중단하는 원인이 될 수 있습니다.
세분화 분석
약제 분류별로는 조절된 난소 자극에서 핵심적인 역할을 하는 고나도트로핀이 시장을 독점하고 있습니다. ‘기타’ 부문은 연평균 성장률(CAGR) 8.04%를 나타낼 것으로 예측됩니다.
약제별로는 FSH가 난포 발육 및 체외수정(IVF) 프로토콜에서 널리 사용되고 있어, 2025년에는 가장 큰 시장 점유율을 차지했습니다. 세트로렐릭스는 연평균 성장률(CAGR) 9.47%를 나타낼 것으로 예측됩니다.
치료법별로는 난소 자극, 배란 유도, 난자 채취 준비, 황체 유지의 각 단계에서 불임 치료제가 필요하기 때문에 ART/IVF 주기 지원이 시장을 주도하고 있습니다. 남성 불임 치료는 연평균 성장률(CAGR) 6.86%를 나타낼 것으로 예측됩니다.
투여 경로별로는 정확한 투여가 가능하다는 점과 고나도트로핀 및 배란 유도제의 광범위한 사용으로 인해 주사제가 주류를 이루고 있습니다. ‘기타’ 부문은 연평균 성장률(CAGR) 10.48%를 나타낼 것으로 예측됩니다.
최종 사용자별로는 2025년에 불임 치료 클리닉이 시장을 주도했으나, 전문 클리닉은 연평균 성장률(CAGR) 7.01%로 확대될 것으로 예측됩니다.
지역별 전망
2025년에는 북미가 10억 4,000만 달러로 1위를 차지했습니다. 미국 시장은 2026년에 10억 3,000만 달러에 달할 것으로 추정되며, 이는 세계 매출의 약 31.71%를 차지합니다.
유럽은 2026년에 8억 7,000만 달러에 달하며, 연평균 성장률(CAGR) 5.27%를 나타낼 것으로 예측됩니다. 독일과 영국은 각각 2억 달러, 1억 8,000만 달러로 추산됩니다.
아시아태평양은 2026년에 8억 9,000만 달러에 달할 것으로 예측됩니다. 중국, 일본, 인도는 각각 약 2억 7,000만 달러, 1억 9,000만 달러, 1억 2,000만 달러에 이를 것으로 예측됩니다.
라틴아메리카는 2026년에 1,900만 달러에 달할 것으로 예측되는 반면, GCC(걸프협력회의) 지역의 불임 치료제 시장은 700만 달러로 추산됩니다. 남아프리카공화국은 약 200만 달러로 예측됩니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 불임 치료제 시장 분석, 인사이트, 예측, 2021년-2034년
제6장 북미의 불임 치료제 시장 분석, 인사이트, 예측, 2021년-2034년
제7장 유럽의 불임 치료제 시장 분석, 인사이트, 예측, 2021년-2034년
제8장 아시아태평양의 불임 치료제 시장 분석, 인사이트, 예측, 2021년-2034년
제9장 라틴아메리카 불임 치료제 시장 분석, 인사이트, 예측, 2021년-2034년
제10장 중동 및 아프리카의 불임 치료제 시장 분석, 인사이트, 예측, 2021년-2034년
제11장 경쟁 분석
LSH 26.10.22Growth Factors of fertility drugs Market
The global fertility drugs market size was valued at USD 3.05 billion in 2025 and is projected to grow from USD 3.24 billion in 2026 to USD 5.25 billion by 2034, exhibiting a CAGR of 6.22% during the 2026-2034 forecast period. North America dominated the market with a 34.1% share in 2025, representing a regional market value of approximately USD 1.04 billion.
Fertility drugs are medicines used to regulate reproductive hormones, stimulate ovulation, support follicle and egg development, and improve outcomes in assisted reproductive procedures such as IVF and IUI. They are widely used for ovulatory disorders, unexplained infertility, polycystic ovary syndrome, diminished ovarian reserve, and controlled ovarian stimulation. Rising infertility prevalence, delayed parenthood, growing awareness, and wider access to fertility clinics are supporting market expansion.
Fertility Drugs Market Trends
Early Infertility Diagnosis and Treatment Awareness Gain Importance
Growing awareness of infertility as a common reproductive health condition is encouraging more patients to seek diagnosis and treatment. Increasing use of ovulation induction therapies, gonadotropins, hormonal treatments, and luteal phase support medicines is strengthening product demand.
The expansion of fertility benefits and affordability programs is another important trend. Government initiatives, employer-supported healthcare benefits, and pharmaceutical access programs are helping reduce medication costs and improve treatment availability.
Market Drivers
Delayed Parenthood and Rising Maternal Age Drive Demand
Increasing maternal age is a major market driver as more individuals postpone parenthood due to education, careers, economic considerations, and changing family preferences. As fertility naturally declines with age, demand is rising for ovulation induction, controlled ovarian stimulation, IVF, and IUI treatments.
Growing ART procedure volumes, expanding fertility clinic networks, and continued drug pipeline development are also contributing to market growth.
Market Restraints
Safety Concerns Associated with Hormonal Stimulation Limit Adoption
Fertility medicines, particularly gonadotropins used during ovarian stimulation, can cause adverse effects such as ovarian hyperstimulation syndrome. These risks require careful patient monitoring and specialist supervision.
High out-of-pocket costs, uneven reimbursement, and limited access to specialist reproductive healthcare may further restrict adoption, particularly in developing markets.
Market Opportunities
Employer and Insurance Fertility Benefits Create Opportunities
Expansion of fertility coverage through employers and insurers presents significant growth potential. Reduced out-of-pocket medication expenses can encourage patients to begin and continue fertility treatment.
Greater reimbursement support can also increase utilization of IVF-related fertility drugs, creating opportunities for manufacturers, pharmacies, and fertility care providers.
Market Challenges
Uncertain treatment success remains a major challenge. Fertility treatments do not guarantee pregnancy or live birth, and some patients require multiple cycles. Repeated treatment increases medication costs, emotional stress, and treatment fatigue, which may cause patients to delay or discontinue therapy.
Segmentation Analysis
By drug class, gonadotropins dominate due to their central role in controlled ovarian stimulation. The others category is projected to grow at an 8.04% CAGR.
By drug, FSH held the largest market share in 2025 because of its extensive use in follicle development and IVF protocols. Cetrorelix is projected to grow at a 9.47% CAGR.
By treatment, ART/IVF cycle support dominates as fertility medicines are required across ovarian stimulation, ovulation triggering, egg retrieval preparation, and luteal support. Male fertility treatment is projected to grow at a 6.86% CAGR.
By route of administration, injectable drugs dominate due to precise dosing and widespread use of gonadotropins and trigger medicines. The others segment is projected to grow at a 10.48% CAGR.
By end user, fertility clinics led the market in 2025, while specialty clinics are projected to expand at a 7.01% CAGR.
Regional Outlook
North America led with USD 1.04 billion in 2025. The U.S. market is estimated to reach USD 1.03 billion in 2026, representing approximately 31.71% of global revenues.
Europe is projected to reach USD 0.87 billion in 2026 and grow at a 5.27% CAGR. Germany and the U.K. are estimated at USD 0.20 billion and USD 0.18 billion, respectively.
Asia Pacific is expected to reach USD 0.89 billion in 2026. China, Japan, and India are projected at approximately USD 0.27 billion, USD 0.19 billion, and USD 0.12 billion, respectively.
Latin America is projected to reach USD 0.19 billion in 2026, while the GCC fertility drugs market is estimated at USD 0.07 billion. South Africa is projected at approximately USD 0.02 billion.
Competitive Landscape
Major companies include Merck KGaA, Ferring B.V., Organon & Co., IBSA Institut Biochimique SA, Gedeon Richter, Theramex, Livzon Pharmaceutical Group, LG Chem, Bharat Serums and Vaccines, and Lupin Limited. Competition centers on injectable fertility therapies, biosimilars, regulatory approvals, product pipelines, affordability initiatives, and geographic expansion.
Key Industry Developments
In February 2026, EMD Serono expanded access pathways for its IVF medicines, including Gonal-f, Ovidrel, and Cetrotide, in the U.S. In 2025, Ferring advanced follitropin delta research, Organon expanded its fertility manufacturing presence, and Gedeon Richter collaborated with Granata Bio on recombinant FSH development.
Conclusion
The fertility drugs market is expected to maintain steady growth as delayed parenthood, infertility awareness, ART adoption, and fertility clinic expansion increase worldwide. The market is projected to rise from USD 3.05 billion in 2025 to USD 3.24 billion in 2026 and reach USD 5.25 billion by 2034, growing at a 6.22% CAGR. Broader fertility benefits, improved treatment access, drug innovation, and rising IVF utilization will remain the major factors shaping market growth through 2034.
Segmentation By Drug Class, Drug, Treatment, Route of Administration, End User, and Region
By Drug Class
- Ovulation Induction Agents
- Gonadotropins
- hCG-based Trigger Drugs
- GnRH Agonists
- GnRH Antagonists
- Progesterone/Luteal Phase Support Drugs
- Others
By Drug
- Clomiphene Citrate
- Letrozole
- FSH
- hMG
- hCG
- Progesterone
- Cetrorelix
- Ganirelix
- Leuprolide
- Triptorelin
- Others
By Treatment
- ART/IVF Cycle Support
- Non-ART Female Fertility Treatment
- Male Fertility Treatment
By Route of Administration
- Injectable
- Oral
- Vaginal
- Others
By End User
- Fertility Clinics
- Hospitals
- Specialty Clinics
- Homecare/Self-administration Settings
- Others
By Region
- North America (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 3.5. Market Challenges
4. Key Insights
- 4.1. Prevalence of Key Fertility Disorders, By Key Regions, Countries
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Overview of Regulatory Scenario, By Key Regions/Countries
- 4.4. New Product Launches, By Key Players
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
5. Global Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. Ovulation Induction Agents
- 5.1.2. Gonadotropins
- 5.1.3. hCG-based Trigger Drugs
- 5.1.4. GnRH Agonists
- 5.1.5. GnRH Antagonists
- 5.1.6. Progesterone/Luteal Phase Support Drugs
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Drug
- 5.2.1. Clomiphene Citrate
- 5.2.2. Letrozole
- 5.2.3. FSH
- 5.2.4. hMG
- 5.2.5. hCG
- 5.2.6. Progesterone
- 5.2.7. Cetrorelix
- 5.2.8. Ganirelix
- 5.2.9. Leuprolide
- 5.2.10. Triptorelin
- 5.2.11. Others
- 5.3. Market Analysis, Insights and Forecast - By Treatment
- 5.3.1. ART/IVF Cycle Support
- 5.3.2. Non-ART Female Fertility Treatment
- 5.3.3. Male Fertility Treatment
- 5.4. Market Analysis, Insights and Forecast - By Route of Administration
- 5.4.1. Injectable
- 5.4.2. Oral
- 5.4.3. Vaginal
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast - By End User
- 5.5.1. Fertility Clinics
- 5.5.2. Hospitals
- 5.5.3. Specialty Clinics
- 5.5.4. Homecare/Self-administration Settings
- 5.5.5. Others
- 5.6. Market Analysis, Insights and Forecast - Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. Ovulation Induction Agents
- 6.1.2. Gonadotropins
- 6.1.3. hCG-based Trigger Drugs
- 6.1.4. GnRH Agonists
- 6.1.5. GnRH Antagonists
- 6.1.6. Progesterone/Luteal Phase Support Drugs
- 6.1.7. Others s
- 6.2. Market Analysis, Insights and Forecast - By Drug
- 6.2.1. Clomiphene Citrate
- 6.2.2. Letrozole
- 6.2.3. FSH
- 6.2.4. hMG
- 6.2.5. hCG
- 6.2.6. Progesterone
- 6.2.7. Cetrorelix
- 6.2.8. Ganirelix
- 6.2.9. Leuprolide
- 6.2.10. Triptorelin
- 6.2.11. Others
- 6.3. Market Analysis, Insights and Forecast - By Treatment
- 6.3.1. ART/IVF Cycle Support
- 6.3.2. Non-ART Female Fertility Treatment
- 6.3.3. Male Fertility Treatment
- 6.4. Market Analysis, Insights and Forecast - By Route of Administration
- 6.4.1. Injectable
- 6.4.2. Oral
- 6.4.3. Vaginal
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast - By End User
- 6.5.1. Fertility Clinics
- 6.5.2. Hospitals
- 6.5.3. Specialty Clinics
- 6.5.4. Homecare/Self-administration Settings
- 6.5.5. Others
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. Ovulation Induction Agents
- 7.1.2. Gonadotropins
- 7.1.3. hCG-based Trigger Drugs
- 7.1.4. GnRH Agonists
- 7.1.5. GnRH Antagonists
- 7.1.6. Progesterone/Luteal Phase Support Drugs
- 7.1.7. Others s
- 7.2. Market Analysis, Insights and Forecast - By Drug
- 7.2.1. Clomiphene Citrate
- 7.2.2. Letrozole
- 7.2.3. FSH
- 7.2.4. hMG
- 7.2.5. hCG
- 7.2.6. Progesterone
- 7.2.7. Cetrorelix
- 7.2.8. Ganirelix
- 7.2.9. Leuprolide
- 7.2.10. Triptorelin
- 7.2.11. Others
- 7.3. Market Analysis, Insights and Forecast - By Treatment
- 7.3.1. ART/IVF Cycle Support
- 7.3.2. Non-ART Female Fertility Treatment
- 7.3.3. Male Fertility Treatment
- 7.4. Market Analysis, Insights and Forecast - By Route of Administration
- 7.4.1. Injectable
- 7.4.2. Oral
- 7.4.3. Vaginal
- 7.4.4. Others
- 7.5. Market Analysis, Insights and Forecast - By End User
- 7.5.1. Fertility Clinics
- 7.5.2. Hospitals
- 7.5.3. Specialty Clinics
- 7.5.4. Homecare/Self-administration Settings
- 7.5.5. Others
- 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Italy
- 7.6.5. Spain
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. Ovulation Induction Agents
- 8.1.2. Gonadotropins
- 8.1.3. hCG-based Trigger Drugs
- 8.1.4. GnRH Agonists
- 8.1.5. GnRH Antagonists
- 8.1.6. Progesterone/Luteal Phase Support Drugs
- 8.1.7. Others s
- 8.2. Market Analysis, Insights and Forecast - By Drug
- 8.2.1. Clomiphene Citrate
- 8.2.2. Letrozole
- 8.2.3. FSH
- 8.2.4. hMG
- 8.2.5. hCG
- 8.2.6. Progesterone
- 8.2.7. Cetrorelix
- 8.2.8. Ganirelix
- 8.2.9. Leuprolide
- 8.2.10. Triptorelin
- 8.2.11. Others
- 8.3. Market Analysis, Insights and Forecast - By Treatment
- 8.3.1. ART/IVF Cycle Support
- 8.3.2. Non-ART Female Fertility Treatment
- 8.3.3. Male Fertility Treatment
- 8.4. Market Analysis, Insights and Forecast - By Route of Administration
- 8.4.1. Injectable
- 8.4.2. Oral
- 8.4.3. Vaginal
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast - By End User
- 8.5.1. Fertility Clinics
- 8.5.2. Hospitals
- 8.5.3. Specialty Clinics
- 8.5.4. Homecare/Self-administration Settings
- 8.5.5. Others
- 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.6.1. China
- 8.6.2. Japan
- 8.6.3. India
- 8.6.4. Southeast Asia
- 8.6.5. Australia
- 8.6.6. Rest of Asia Pacific
9. Latin America Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. Ovulation Induction Agents
- 9.1.2. Gonadotropins
- 9.1.3. hCG-based Trigger Drugs
- 9.1.4. GnRH Agonists
- 9.1.5. GnRH Antagonists
- 9.1.6. Progesterone/Luteal Phase Support Drugs
- 9.1.7. Others s
- 9.2. Market Analysis, Insights and Forecast - By Drug
- 9.2.1. Clomiphene Citrate
- 9.2.2. Letrozole
- 9.2.3. FSH
- 9.2.4. hMG
- 9.2.5. hCG
- 9.2.6. Progesterone
- 9.2.7. Cetrorelix
- 9.2.8. Ganirelix
- 9.2.9. Leuprolide
- 9.2.10. Triptorelin
- 9.2.11. Others
- 9.3. Market Analysis, Insights and Forecast - By Treatment
- 9.3.1. ART/IVF Cycle Support
- 9.3.2. Non-ART Female Fertility Treatment
- 9.3.3. Male Fertility Treatment
- 9.4. Market Analysis, Insights and Forecast - By Route of Administration
- 9.4.1. Injectable
- 9.4.2. Oral
- 9.4.3. Vaginal
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast - By End User
- 9.5.1. Fertility Clinics
- 9.5.2. Hospitals
- 9.5.3. Specialty Clinics
- 9.5.4. Homecare/Self-administration Settings
- 9.5.5. Others
- 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. Ovulation Induction Agents
- 10.1.2. Gonadotropins
- 10.1.3. hCG-based Trigger Drugs
- 10.1.4. GnRH Agonists
- 10.1.5. GnRH Antagonists
- 10.1.6. Progesterone/Luteal Phase Support Drugs
- 10.1.7. Others s
- 10.2. Market Analysis, Insights and Forecast - By Drug
- 10.2.1. Clomiphene Citrate
- 10.2.2. Letrozole
- 10.2.3. FSH
- 10.2.4. hMG
- 10.2.5. hCG
- 10.2.6. Progesterone
- 10.2.7. Cetrorelix
- 10.2.8. Ganirelix
- 10.2.9. Leuprolide
- 10.2.10. Triptorelin
- 10.2.11. Others
- 10.3. Market Analysis, Insights and Forecast - By Treatment
- 10.3.1. ART/IVF Cycle Support
- 10.3.2. Non-ART Female Fertility Treatment
- 10.3.3. Male Fertility Treatment
- 10.4. Market Analysis, Insights and Forecast - By Route of Administration
- 10.4.1. Injectable
- 10.4.2. Oral
- 10.4.3. Vaginal
- 10.4.4. Others
- 10.5. Market Analysis, Insights and Forecast - By End User
- 10.5.1. Fertility Clinics
- 10.5.2. Hospitals
- 10.5.3. Specialty Clinics
- 10.5.4. Homecare/Self-administration Settings
- 10.5.5. Others
- 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.6.1. GCC
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Merck KGaA
- 11.2.2. Ferring B.V.
- 11.2.3. Organon & Co.
- 11.2.4. IBSA Institut Biochimique SA
- 11.2.5. Gedeon Richter Plc.
- 11.2.6. Theramex
- 11.2.7. Livzon Pharmaceutical Group
- 11.2.8. LG Chem
- 11.2.9. Bharat Serums and Vaccines
- 11.2.10. Lupin Limited.
